Patents by Inventor W. Brad Wan
W. Brad Wan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230055405Abstract: Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of APP RNA in a cell or animal, and in certain instances reducing the amount of APP protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease or disorder. Such symptoms and hallmarks include cognitive impairment, including a decline in memory and language skills, behavioral and psychological symptoms such as apathy and lack of motivation, gait disturbances and seizures, progressive dementia, and abnormal amyloid deposits.Type: ApplicationFiled: July 28, 2021Publication date: February 23, 2023Applicant: Ionis Pharmaceuticals, Inc.Inventors: Huynh-Hoa Bui, Susan M. Freier, Hien Thuy Zhao, Holly Kordasiewicz, Ruben E. Valas, Thazha P. Prakash, W. Brad Wan
-
Publication number: 20220064638Abstract: Provided are compounds, methods, and pharmaceutical compositions for modulating SMN2 RNA and/or protein in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom of a neurodegenerative disorder. Such symptoms include reduced muscle strength; inability or reduced ability to sit upright, to stand, and/or walk; reduced neuromuscular activity; reduced electrical activity in one or more muscles; reduced respiration; inability or reduced ability to eat, drink, and/or breathe without assistance; loss of weight or reduced weight gain; and/or decreased survival.Type: ApplicationFiled: February 26, 2021Publication date: March 3, 2022Applicant: Ionis Pharmaceuticals, Inc.Inventors: Frank Rigo, Thazha P. Prakash, Kar Yun Karen Ling, W. Brad Wan, William John Drury, III
-
Patent number: 10751419Abstract: Provided herein are improved methods for the synthesis of reactive conjugate clusters and intermediates used in such methods. In particular, improvements are provided that enhance the synthesis of reactive conjugate clusters by reducing the number of synthetic steps required. The reactive conjugate clusters prepared using the improved methods don't include any transacylation impurities that are formed using existing methods. The improved methods also provide an increase in overall yield and a cost benefit over existing methods.Type: GrantFiled: September 7, 2018Date of Patent: August 25, 2020Assignee: Ionis Pharmaceuticals, Inc.Inventors: Michael T. Migawa, Jinghua Yu, W. Brad Wan, Sayten P. Patel, Guillermo Vasquez, Garth A. Kinberger, Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
-
Publication number: 20190209694Abstract: Provided herein are improved methods for the synthesis of reactive conjugate clusters and intermediates used in such methods. In particular, improvements are provided that enhance the synthesis of reactive conjugate clusters by reducing the number of synthetic steps required. The reactive conjugate clusters prepared using the improved methods don't include any transacylation impurities that are formed using existing methods. The improved methods also provide an increase in overall yield and a cost benefit over existing methods.Type: ApplicationFiled: September 7, 2018Publication date: July 11, 2019Applicant: Ionis Pharmaceuticals, Inc.Inventors: Michael T. Migawa, Jinghua Yu, W. Brad Wan, Sayten P. Patel, Guillermo Vasquez, Garth A. Kinberger, Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
-
Patent number: 10344275Abstract: The present invention provides oligomeric compounds comprising at least one neutral methoxypropyl phosphonate modified internucleoside linkage. Such oligomeric compounds have one or more improved properties such as selectivity, potency, improved toxicity profile and or improved proinflammatory profile. Such oligomeric compounds have enhanced stability to exposure to base during synthesis. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.Type: GrantFiled: February 8, 2018Date of Patent: July 9, 2019Assignee: Ionis Pharmaceuticals, Inc.Inventors: W. Brad Wan, Michael T. Migawa, Michael Oestergaard, Eric E. Swayze, Punit P. Seth
-
Publication number: 20180305687Abstract: The present invention provides oligomeric compounds comprising at least one neutral methoxypropyl phosphonate modified internucleoside linkage. Such oligomeric compounds have one or more improved properties such as selectivity, potency, improved toxicity profile and or improved proinflammatory profile. Such oligomeric compounds have enhanced stability to exposure to base during synthesis. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.Type: ApplicationFiled: February 8, 2018Publication date: October 25, 2018Applicant: Ionis Pharmaceuticals, Inc.Inventors: W. Brad Wan, Michael T. Migawa, Michael Oestergaard, Eric E. Swayze, Punit P. Seth
-
Patent number: 10098959Abstract: Provided herein are improved methods for the synthesis of reactive conjugate clusters and intermediates used in such methods. In particular, improvements are provided that enhance the synthesis of reactive conjugate clusters by reducing the number of synthetic steps required. The reactive conjugate clusters prepared using the improved methods don't include any transacylation impurities that are formed using existing methods. The improved methods also provide an increase in overall yield and a cost benefit over existing methods.Type: GrantFiled: May 1, 2015Date of Patent: October 16, 2018Assignee: Ionis Pharmaceuticals, Inc.Inventors: Michael T. Migawa, Jinghua Yu, W. Brad Wan, Satyen P. Patel, Guillermo Vasquez, Garth A. Kinberger, Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
-
Patent number: 9926556Abstract: The present invention provides oligomeric compounds comprising at least one neutral methoxypropyl phosphonate modified internucleoside linkage. Such oligomeric compounds have one or more improved properties such as selectivity, potency, improved toxicity profile and or improved proinflammatory profile. Such oligomeric compounds have enhanced stability to exposure to base during synthesis. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.Type: GrantFiled: April 28, 2015Date of Patent: March 27, 2018Assignee: Ionis Pharmaceuticals, Inc.Inventors: W. Brad Wan, Michael T. Migawa, Michael Oestergaard, Eric E. Swayze, Punit P. Seth
-
Patent number: 9701708Abstract: Provided herein are methods for the synthesis of oligomeric compounds wherein the standard coupling protocols are modified when coupling bicyclic nucleosides of Formula I. More particularly, the modified coupling protocols provide for a decrease in the ratio of phosphoramidite solution to activator solution in the coupling reagent with an increased contact time. The modified coupling protocols provide for oligomeric compounds having comparable yields to similar oligomeric compounds having modified nucleosides other than bicyclic nucleosides of Formula I.Type: GrantFiled: January 30, 2014Date of Patent: July 11, 2017Assignee: Ionis Pharmaceuticals, Inc.Inventors: Isaiah E. Cedillo, Michael T. Migawa, W. Brad Wan
-
Publication number: 20170043025Abstract: Provided herein are improved methods for the synthesis of reactive conjugate clusters and intermediates used in such methods. In particular, improvements are provided that enhance the synthesis of reactive conjugate clusters by reducing the number of synthetic steps required. The reactive conjugate clusters prepared using the improved methods don't include any transacylation impurities that are formed using existing methods. The improved methods also provide an increase in overall yield and a cost benefit over existing methods.Type: ApplicationFiled: May 1, 2015Publication date: February 16, 2017Applicant: Ionis Pharmaceuticals, Inc.Inventors: Michael T. Migawa, Jinghua Yu, W. Brad Wan, Satyen P. Patel, Guillermo Vasquez, Garth A. Kinberger, Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
-
Publication number: 20170044526Abstract: The present invention provides oligomeric compounds comprising at least one neutral methoxypropyl phosphonate modified internucleoside linkage. Such oligomeric compounds have one or more improved properties such as selectivity, potency, improved toxicity profile and or improved proinflammatory profile. Such oligomeric compounds have enhanced stability to exposure to base during synthesis. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.Type: ApplicationFiled: April 28, 2015Publication date: February 16, 2017Applicant: Ionis Pharmaceuticals, Inc.Inventors: W. Brad Wan, Michael T. Migawa, Michael Oestergaard, Eric E. Swayze, Punit P. Seth
-
Publication number: 20150368288Abstract: Provided herein are methods for the synthesis of oligomeric compounds wherein the standard coupling protocols are modified when coupling bicyclic nucleosides of Formula I. More particularly, the modified coupling protocols provide for a decrease in the ratio of phosphoramidite solution to activator solution in the coupling reagent with an increased contact time. The modified coupling protocols provide for oligomeric compounds having comparable yields to similar oligomeric compounds having modified nucleosides other than bicyclic nucleosides of Formula I.Type: ApplicationFiled: January 30, 2014Publication date: December 24, 2015Applicant: ISIS PHARMACEUTICALS, INC.Inventors: Isaiah E. Cedillo, Michael T. Migawa, W. Brad Wan
-
Patent number: 8193167Abstract: Compounds and compositions are provided for treatment, prevention, or amelioration of a variety of medical disorders associated with viral infections, cell proliferation and bone metabolism. The compounds provided herein are alkyl esters of phosphonates.Type: GrantFiled: December 10, 2009Date of Patent: June 5, 2012Assignees: The Regents of the University of California, The United States of America, Department of Veterans AffairsInventors: Karl Y. Hostetler, W. Brad Wan
-
Publication number: 20100273742Abstract: Compounds and compositions are provided for treatment, prevention, or amelioration of a variety of medical disorders associated with viral infections, cell proliferation and bone metabolism. The compounds provided herein are alkyl esters of phosphonates.Type: ApplicationFiled: December 10, 2009Publication date: October 28, 2010Applicant: The Regents of the University of CaliforniaInventors: Karl Y. Hostetler, W. Brad Wan
-
Patent number: 7652001Abstract: Compounds and compositions are provided for treatment, prevention, or amelioration of a variety of medical disorders associated with viral infections, cell proliferation and bone metabolism. The compounds provided herein are alkyl esters of phosphonates.Type: GrantFiled: February 7, 2005Date of Patent: January 26, 2010Assignee: The Regents of the University of CaliforniaInventors: Karl Y. Hostetler, W. Brad Wan